Merck pushes on with Consumer Health review

Merck pushes on with Consumer Health review

13 November 2017 - Deborah Wilkes

Merck’s strategic review of its Consumer Health business is gathering momentum, as the company sends out tender packages to interested parties.

Read all about the strategic review – which could see important brands like Bion, Femibion, Nasivin, Neurobion and Seven Seas change hands – in this NEWS EXTRA publication from OTCToolbox.

Merck Consumer Health reported double-digit organic sales growth in the third quarter of 2017. Merck said Consumer Health's global core strategic brands Neurobion, Dolo-Neurobion and Femibion had contributed to organic growth across all major sales regions.

Germany's Merck announced on 5 September 2017 that it is considering a range of strategic options for its Consumer Health business, including divestment. The company said in a statement that a “potential full or partial sale of the business as well as strategic partnerships” were on the table.

Download the publication today to find out more about:
– Merck's timeline for the review
– Basics of the Consumer Health business
– Recent developments at the business
– The growth strategy for Neurobion
– White space opportunities
– Reasons for the review

The News Extra is available to purchase and download immediately from the OTCToolbox website. You can make sure your team is well informed through a Multiple User Licence or a Global Licence.

This essential reading is available free to people with an Annual Subscription to the OTCToolbox website (click here to find out more).

See Payment Options box at the top of this page

For alternative payment options and delivery methods, or other questions, please send an email to

Annual Subscription Holder?

Sign in to continue reading.

Sign In

Back to News Extras

Share this page: